메뉴 건너뛰기




Volumn 13, Issue 5, 2013, Pages 378-379

Sofosbuvir: The final nail in the coffin for hepatitis C?

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; GS 5885; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG;

EID: 84876698027     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70074-4     Document Type: Letter
Times cited : (32)

References (16)
  • 1
    • 84876740954 scopus 로고    scopus 로고
    • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    • published online March 15.
    • Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, published online March 15. http://dx.doi.org/10.1016/S1473-3099(13)70033-1.
    • (2013) Lancet Infect Dis
    • Lawitz, E.1    Lalezari, J.P.2    Hassanein, T.3
  • 2
    • 33747797031 scopus 로고    scopus 로고
    • Treating viral hepatitis C: efficacy, side effects, and complications
    • Manns MP, Wedemeyer H, Cornberg M Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
    • (2006) Gut , vol.55 , pp. 1350-1359
    • Manns, M.P.1    Wedemeyer, H.2    Cornberg, M.3
  • 3
    • 0032547938 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group
    • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
    • (1998) N Engl J Med , vol.339 , pp. 1485-1492
    • McHutchison, J.G.1    Gordon, S.C.2    Schiff, E.R.3
  • 4
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 5
    • 0344201903 scopus 로고    scopus 로고
    • An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
    • Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
    • (2003) Nature , vol.426 , pp. 186-189
    • Lamarre, D.1    Anderson, P.C.2    Bailey, M.3
  • 6
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
    • (2011) N Engl J Med , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone, J.J.2    Bacon, B.R.3
  • 7
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 8
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3
  • 9
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 10
    • 84863519517 scopus 로고    scopus 로고
    • Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting
    • (abstr).
    • Hezode C, Dorival C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012, 56:51. (abstr).
    • (2012) Hepatology , vol.56 , pp. 51
    • Hezode, C.1    Dorival, C.2    Zoulim, F.3
  • 11
    • 84873275651 scopus 로고    scopus 로고
    • Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting
    • Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013, 8:e55285.
    • (2013) PLoS One , vol.8
    • Maasoumy, B.1    Port, K.2    Markova, A.A.3
  • 12
    • 84874107832 scopus 로고    scopus 로고
    • Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    • Lange CM, Zeuzem S Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013, 58:583-592.
    • (2013) J Hepatol , vol.58 , pp. 583-592
    • Lange, C.M.1    Zeuzem, S.2
  • 13
    • 84878976866 scopus 로고    scopus 로고
    • Sofosbuvir with peginterferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    • published online March 15.
    • Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with peginterferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, published online March 15. http://dx.doi.org/10.1016/S0140-6736(13)60247-0.
    • (2013) Lancet
    • Kowdley, K.V.1    Lawitz, E.2    Crespo, I.3
  • 14
    • 84871814966 scopus 로고    scopus 로고
    • Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    • Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
    • (2013) N Engl J Med , vol.368 , pp. 34-44
    • Gane, E.J.1    Stedman, C.A.2    Hyland, R.H.3
  • 15
    • 84872022905 scopus 로고    scopus 로고
    • High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A Inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3
    • LB-2.
    • Sulkowski M, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A Inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. Hepatology 2012, 56. LB-2.
    • (2012) Hepatology , vol.56
    • Sulkowski, M.1    Gardiner, D.F.2    Rodriguez-Torres, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.